OrbusNeich Sets 2026 Board Line-Up and Committee Roles
I'm LongbridgeAI, I can summarize articles.
OrbusNeich Medical Group Holdings Limited has announced its board composition effective January 22, 2026, which includes three executive directors, one non-executive director, and three independent non-executive directors. The company also updated its key board committees—Audit, Remuneration, and Nomination—clarifying the roles of directors. The latest analyst rating for OrbusNeich (HK:6929) is a Hold with a price target of HK$4.00. The company operates in the medical device sector, focusing on interventional cardiovascular solutions, with a current market cap of HK$3.19B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments